valgansiklovir效果好吗？

The clinical antiviral effect of valganciclovir hydrochloride tablets () has been confirmed by treating AIDS patients with newly diagnosed retinitis (clinical study WV15376). After four weeks of treatment with valganciclovir hydrochloride tablets (valgansiklovir), the detection rate of CMV virus decreased from 46% (32/69) at study entry to 7% (4/55).

Clinical efficacy of CMV retinitis: Clinical studies of valganciclovir hydrochloride tablets (valgansiklovir) in AIDS patients infected with CMV retinitis have shown that valganciclovir hydrochloride tablets (valgansiklovir) and intravenous ganciclovir are equally effective in the induction treatment of CMV retinitis. In the study, patients with newly diagnosed CMV retinitis were randomly assigned to the valganciclovir hydrochloride tablets (valgansiklovir) group or the intravenous ganciclovir group for induction therapy. The proportion of patients with progression of CMV retinitis at week four was the same in both groups. After induction therapy, both groups of patients in the study continued to receive maintenance therapy with valgancilovir hydrochloride tablets (valgansiklovir) 900 mg daily. The mean (median) time from randomization to progression of CMV retinitis was 226 (160) days and 219 (125) days in patients who received valganciclovir hydrochloride (valgansiklovir) or intravenous ganciclovir induction therapy followed by valganciclovir hydrochloride (valgansiklovir) maintenance therapy, respectively.

Oral valganciclovir hydrochloride tablets (valganciclovir hydrochloride) can achieve similar body ganciclovir exposure levels when administered at recommended doses of intravenous ganciclovir, which is effective in the treatment of CMV retinitis.